Introduction and Objective: Assessment of β-cell secretory capacity by glucose-potentiation of arginine-induced insulin secretion (AIRpot) provides a gold-standard measure of functional β-cell mass post-islet transplantation. However, glucose-potentiated arginine (GPA) testing procedures are intensive and not feasible for routine islet graft monitoring. We examined the association between simple measures of islet graft β-cell function (MMTT C-peptide and BETA-2 score) and β-cell secretory capacity (AIRpot) in a longitudinal cohort.

Methods: Individuals with T1D complicated by problematic hypoglycemia underwent intrahepatic allogeneic islet transplantation under the Clinical Islet Transplantation 07 (CIT07) protocol between 2008 - 2012. MMTT and GPA procedures were completed on adjacent days at 2.5 months and yearly up to 7 years post-transplant. Relationships between measures were assessed by repeated-measures correlation analysis.

Results: 11 individuals (mean±SE age: 45±3 years; T1D duration: 28±4 years; and BMI: 25±1 kg/m2) received 694,895±48,498 islet equivalents over one (n=7) or two (n=4) transplants. 63 paired procedures in individuals with sustained islet graft function were assessed, representing an average of 5.73 repeated measures per participant. MMTT C-peptide correlated moderately with AIRpot at 60-min (r2=.16; P<0.01), 90-min (r2=.24; P<0.001) and at peak (r2=.22; P<0.001). Assessment of C-peptide/glucose ratio improved the relationship at 60-min (r2=.20; P<0.001). BETA-2 score was a better predictor of AIRpot (r2=.23; P<0.001) than fasting C-peptide/glucose (r2=.14; P<0.01).

Conclusion: MMTT C-peptide and BETA-2 score predict underlying β-cell secretory capacity however with only moderate effect sizes. The BETA-2 score holds additional value as a fasting measure that can inform changes in β-cell secretory capacity.

Disclosure

A. Flatt: None. A.M. Matus: None. R.J. Gallop: None. E.M. Markmann: None. C.V. Dalton-Bakes: None. A. Peleckis: None. C. Liu: None. A. Naji: None. M.R. Rickels: Consultant; Vertex Pharmaceuticals Incorporated, Sernova, Corp. Research Support; Dompé.

Funding

National Institutes of Health Public Health Services Research Grants (R01 DK091331; U01 DK070430; UL1 TR000003; UL1 TR001878; and P30 DK19525)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.